{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dolutegravir+50+MG", "query": { "intervention": "Dolutegravir 50 MG" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 82, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dolutegravir+50+MG&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T19:12:34.626Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01227824", "title": "A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus I" ], "interventions": [ { "name": "GSK1349572 (dolutegravir)", "type": "DRUG" }, { "name": "raltegravir", "type": "DRUG" }, { "name": "GSK1349572 Placebo", "type": "OTHER" }, { "name": "ABC/3TC", "type": "OTHER" }, { "name": "TDF/FTC", "type": "OTHER" }, { "name": "raltegravir Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 828, "start_date": "2010-10-19", "completion_date": "2016-12-27", "has_results": true, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-09-25T19:12:34.626Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01227824" }, { "nct_id": "NCT03639311", "title": "Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB LA", "type": "DRUG" }, { "name": "RPV LA", "type": "DRUG" }, { "name": "RPV", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2018-09-24", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-09-25T19:12:34.626Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03639311" }, { "nct_id": "NCT01967771", "title": "Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "DTG", "type": "DRUG" }, { "name": "CBZ", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 16, "start_date": "2013-10", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-01-27", "last_synced_at": "2026-09-25T19:12:34.626Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01967771" }, { "nct_id": "NCT02263326", "title": "Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "dolutegravir", "type": "DRUG" }, { "name": "lamivudine", "type": "DRUG" }, { "name": "Continue current antiretroviral regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Babafemi Taiwo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2014-12", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2019-10-14", "last_synced_at": "2026-09-25T19:12:34.626Z", "location_count": 7, "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02263326" }, { "nct_id": "NCT01231529", "title": "GSK1349572 Hepatic Impairment Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects", "Hepatic Impairment", "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "GSK1349572", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2010-11-19", "completion_date": "2011-06-04", "has_results": false, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-09-25T19:12:34.626Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231529" }, { "nct_id": "NCT02422797", "title": "Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DTG 50 mg", "type": "DRUG" }, { "name": "RPV 25 mg", "type": "DRUG" }, { "name": "CAR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2015-04-21", "completion_date": "2023-05-25", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-09-25T19:12:34.626Z", "location_count": 13, "location_summary": "Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Vero Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02422797" }, { "nct_id": "NCT02519777", "title": "Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Placebo for maraviroc (MVC)", "type": "DRUG" }, { "name": "Placebo for dolutegravir (DTG)", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Maraviroc (MVC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2016-04-21", "completion_date": "2021-01-05", "has_results": true, "last_update_posted_date": "2022-04-22", "last_synced_at": "2026-09-25T19:12:34.626Z", "location_count": 23, "location_summary": "Los Angeles, California • San Diego, California • Torrance, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02519777" }, { "nct_id": "NCT03984838", "title": "Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2019-06-17", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2020-07-14", "last_synced_at": "2026-09-25T19:12:34.626Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03984838" }, { "nct_id": "NCT03816696", "title": "Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2019-01-23", "completion_date": "2019-04-10", "has_results": true, "last_update_posted_date": "2020-03-19", "last_synced_at": "2026-09-25T19:12:34.626Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03816696" }, { "nct_id": "NCT02105987", "title": "A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "ABC/DTG/3TC FDC", "type": "DRUG" }, { "name": "Ongoing cART regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 555, "start_date": "2014-04", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-09-25T19:12:34.626Z", "location_count": 87, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02105987" } ] }